а



Figure S1

a : Picture from the ultracentrifuged pellet from culture supernatant of EL4.b: Acetylcholine esterase activity in ultracentrifuged fraction (TDE).



Figure S2 :Stat3 activation in purified MDSCs

Purified splenic MDSCs from naïve mice were treated with TCS or TDSF or TDE. pStat3 expression was determined by FACS analysis. Data are Mean ± s.d. fluorescence intensity (n=3)



Figure S3. Expansion of MDSCs by GM-CSF

Bone marrow from naïve mice were cultured 3 days in complete medium alone or with TDSF or TDSF + blocking anti GM-CSF or rGM-CSF. The percentage of $Gr1^+$ CD11b⁺ precursor cells ± s.d. was determined by flow cytometry.



Figure S4. NFkB p65 transcriptional activition by TDE and TDSF

(Left panel) MDSC clone were stimulated with TDE for 2h, 4h or 6h . Then NF κ B p65 transcriptional activity was determined with TransAm assay.

(Right panel) MDSC clone were stimulated with TDSF or GM-CSF for 2h. Then NF κ B p65 transcriptional activity was determined with TransAm assay.



Figure S5. pStat3 expression in MDSCs Subpopulations

MDSC from tumor-bearing mice were analysed for Ly6C Ly6G CD11b and pStat3 expression by cytometry.

Monocytic MDSC were characterized by Ly6C^{high}Ly6G⁻CD11b⁺; granulocytic MDSC by Ly6C^{intermediate} Ly6G⁺ CD11b⁺.



Figure S6. Cytokines production by tumor cells and TDE

A. Tumor cell supernatant SCF, PGE2, IL-10 and IL-6 were determined by ELISA.

B. PGE2 levels in TDE were determined by ELISA.



Figure S7. Cytokines production by MDSCs.

Purified MDSC from naïve mice were treated 24h with complete conditioned medium (CM) or soluble fraction (TDSF) or exosome (TDE) obtained from CT26, TS/A, EL4 and 3T3 cell cultures before and after ultracentrifugation (UC). IL-1 β (a), TNF- α (b), IL-10 (c) and VEGF (d) concentrations were determined by ELISA.





a. MDSCs from wild-type or TLR2-, TLR4-, MyD88- or TRIF-deficient tumor-free mice were cultured for 24h with PBS alone or supplemented with LPS (10 ng/mL) or Poly(I:C) (50μ g/mL), then IL-6 concentrations were determined by ELISA in the supernatant.

b. MDSCs from wild-type or TLR2-, TLR4-, MyD88- or TRIF-deficient tumor-free mice were cultured for 24h with PBS alone or supplemented with rIL-6 (10ng/mL). pStat3 expression was determined by FACS analysis on MDSCs gated cells. MFI = mean fluorescence intensity ± s.d.



Figure S9. Expression of Hsp72, Tsg101 and Grp72 in exosome and other microparticules

EL4- exosome were separated from other microparticules by ultracentrifugation on 30% sucrose/D2O. Both fractions were blotted for tsg101 (exosomal protein), Grp94 (endoplasmic reticulum protein) and Hsp72.



Figure S10. IL-6 and TNF-α production by MDSCs

Naïve MDSCs were stimulated 24h with rHsp72 or PAM3CSK4 or PAM3CSK4 plus a blocking anti Hsp72. IL-6 and TNF- α in the supernatant were determined by ELISA.



Figure S11. Erk ,Stat3 and NFkB activation by Hsp72 in MDSCs

MDSC clone were stimulated with rHsp72, pERK (a) and pStat3 (b) expression was determined western blotting.

MDSC clone were stimulated with rHsp72, then NF κ B p65 (c) and Stat3 (d) transcriptional activity was determined with TransAm assay.



Figure S12. Hsp72 expression in CT26 clones transfected with ShRNA targeting Hsp72

Hsp72 expression was determined by western blotting in shRNA Mock CT26, and in 5 different shRNA Hsp72 CT26 clones. Hsp72 expression was also determined in TDE from shRNA Mock CT26 and shRNA Hsp72 CT26 clones H96 and H97.



Figure S13. Tumor growth in wild type and *n ude* **mice after cyclophosphamide treatment.** Wild-type and *nude* mice were subcutaneously injected with 1.10⁶ TS/A, EL4 or CT26 tumor cells. 10 days later, mice were injected with PBS or cyclophosphamide (CTX) (100 mg/kg). Tumor volume was determined using a caliper.



Figure S14. Hsc73 and Hsp72 expression in H23 and H23 TDE was determined by western blotting.